Inclusion Criteria:  All patients who  18-99 years of age have a recorded clinical diagnosis of asthma (ICD-10 Code: J45) undergo moderate-serve asthma treatment according to GINA/DAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy  Asthma treatment for a minimum of 12 weeks prior to screening visit  Group 1 and 2 - T2-high asthma with or without polyps: FeNO > 25 ppB had either two times >= 250 eosinophils /µl measured in the blood OR one measurement of blood eosinophils >= 250 cells/µl (one of the two measurements at the screening visit) and/or one measurement of sputum eosinophils > 2% within the last 12 months  Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)  Group 3 - CRSwNP in absence of asthma: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines Evidence of Type 2 inflammation: eosinophils >= 250 cells/µl measured in the blood OR total IgE >100 kU/L at the screening visit Absence of asthma and N-ERD Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed  Exclusion Criteria:  Pregnancy (as determined by ß-HCG test) Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity Patients undergoing chronic oral corticosteroid therapy  Patients with any other confounding underlying lung disorder including but not limited to:  Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia Cystic fibrosis, any known parasitic infections, and lung cancer Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study Patients with clinically meaningful comorbidity as determined by the evaluating committee Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit Intake of a burst of systemic corticosteroids 4 weeks prior to any visit. Immunosuppressive treatment (e.g. cyclosporine) Drug and alcohol abuses Current smoker Former smoker if stopped smoking <6 months and/or has >10 pack-years